JP2022536659A5 - - Google Patents

Info

Publication number
JP2022536659A5
JP2022536659A5 JP2021573301A JP2021573301A JP2022536659A5 JP 2022536659 A5 JP2022536659 A5 JP 2022536659A5 JP 2021573301 A JP2021573301 A JP 2021573301A JP 2021573301 A JP2021573301 A JP 2021573301A JP 2022536659 A5 JP2022536659 A5 JP 2022536659A5
Authority
JP
Japan
Prior art keywords
antibody
resin
seq
approximately
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536659A (ja
JP7753105B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037069 external-priority patent/WO2020252072A1/en
Publication of JP2022536659A publication Critical patent/JP2022536659A/ja
Publication of JP2022536659A5 publication Critical patent/JP2022536659A5/ja
Priority to JP2025022330A priority Critical patent/JP2025087720A/ja
Application granted granted Critical
Publication of JP7753105B2 publication Critical patent/JP7753105B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573301A 2019-06-10 2020-06-10 抗体の精製方法及びその組成物 Active JP7753105B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025022330A JP2025087720A (ja) 2019-06-10 2025-02-14 抗体の精製方法及びその組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859580P 2019-06-10 2019-06-10
US62/859,580 2019-06-10
PCT/US2020/037069 WO2020252072A1 (en) 2019-06-10 2020-06-10 Antibody purification methods and compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025022330A Division JP2025087720A (ja) 2019-06-10 2025-02-14 抗体の精製方法及びその組成物

Publications (3)

Publication Number Publication Date
JP2022536659A JP2022536659A (ja) 2022-08-18
JP2022536659A5 true JP2022536659A5 (https=) 2024-02-08
JP7753105B2 JP7753105B2 (ja) 2025-10-14

Family

ID=73782230

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573301A Active JP7753105B2 (ja) 2019-06-10 2020-06-10 抗体の精製方法及びその組成物
JP2025022330A Pending JP2025087720A (ja) 2019-06-10 2025-02-14 抗体の精製方法及びその組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025022330A Pending JP2025087720A (ja) 2019-06-10 2025-02-14 抗体の精製方法及びその組成物

Country Status (14)

Country Link
US (1) US20220259291A1 (https=)
EP (1) EP3980119A4 (https=)
JP (2) JP7753105B2 (https=)
CN (4) CN114025843B (https=)
AR (1) AR119268A1 (https=)
AU (1) AU2020290999A1 (https=)
BR (1) BR112021024848A2 (https=)
CA (1) CA3143169A1 (https=)
IL (1) IL288830A (https=)
MA (1) MA56132A (https=)
MX (1) MX2021015302A (https=)
PL (1) PL439807A1 (https=)
TW (1) TW202112800A (https=)
WO (1) WO2020252072A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019198099A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Stable antibody formulation
EP4380948A4 (en) * 2021-08-05 2025-07-16 Dr Reddys Laboratories Ltd METHOD FOR PURIFYING AN ANTIBODY COMPOSITION BY MEANS OF CATION EXCHANGE CHROMATOGRAPHY
WO2023031965A1 (en) * 2021-09-03 2023-03-09 Dr. Reddy’S Laboratories Limited Method to obtain a purified antibody composition
WO2023180523A1 (en) * 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO2006026759A2 (en) * 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
JP6592426B2 (ja) * 2013-03-15 2019-10-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
PL3116891T3 (pl) * 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
WO2018104893A1 (en) * 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life

Similar Documents

Publication Publication Date Title
JP2022536659A5 (https=)
JP6913066B2 (ja) 高純度および優れた収率の正確に折り畳まれたエタネルセプト
EP2791176B1 (en) A method of antibody purification
CN102791726B (zh) 纯化免疫球蛋白溶液的方法
KR100372209B1 (ko) 항체정제법
EP3247718B1 (en) Modulation of charge variants in a monoclonal antibody composition
RU2651483C2 (ru) Способы очистки антител
JP2011523408A (ja) 抗体精製方法
JP2012507557A5 (https=)
EP3067367A1 (en) Method for purifying recombinant protein
JP2015511637A (ja) アフィニティークロマトグラフィーマトリックス
JP6335785B2 (ja) ミックスモード抗体アフィニティー分離マトリックスとそれを用いた精製方法および標的分子
MX2013004627A (es) Metodo optimizado para captura de anticuerpo por cromatografia de modo mixto.
US20230124565A1 (en) Non-protein a purification method for adalimumab
JP2015502959A (ja) ＩｇＧ２ジスルフィドアイソフォームの分離
JP2019504060A (ja) モノクローナル抗体のアイソフォームを分離するための方法
JP2023523823A (ja) タンパク質の精製の改善されたプロセス
CN112574321A (zh) 一种捕获单克隆抗体-肿瘤坏死因子融合蛋白的亲和纯化方法
KR20140062044A (ko) 양이온 및 음이온 교환 크로마토그래피 방법
JP2017507132A (ja) 抗体プロセス
US20230079633A1 (en) Optimized method for bevacizumab purification
JP2014094936A (ja) 抗体の精製方法
TW202241924A (zh) 一種雙特異性抗體的純化方法
JP6115126B2 (ja) ヒトＩｇＧ３の精製方法
TW202003555A (zh) 用於純化重組多肽之方法